AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34773995 — intervention group
Group type: COMPARATOR
Intervention: Control group (adductor canal blocks and periarticular infiltration without SNB)
Number of subjects: 50
Study 33346848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiome transfer (FMT)
Number of subjects: 87
Study 33346848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 34962979 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60/30 mg
Number of subjects: 841
Study 34962979 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30/15 mg
Number of subjects: 841
Study 34962979 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 841
Study 34788550 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea Extract (GTE) 400 mg every 12 hours for 3 months
Number of subjects: 39
Study 33564423 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (LINA) 5mg
Number of subjects: 6979
Study 33564423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 6979
Study 32134490 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV prevention interventions (specifics not provided)
Number of subjects: 0
Study 32134490 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (specifics not provided)
Number of subjects: 0
Study 35522352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy Self‐Management Training program (OSMT) with goal setting
Number of subjects: 524
Study 35522352 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) without goal setting
Number of subjects: 524
Study 34324636 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltorexant 20 mg
Number of subjects: 160
Study 34324636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32117519 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter bag drainage device
Number of subjects: 41
Study 32117519 — intervention group
Group type: COMPARATOR
Intervention: Underwater seal drainage bottle
Number of subjects: 41
Study 32964238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 0
Study 32964238 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ)
Number of subjects: 0
Study 32964238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ileal pyroptosis <14 positive cells/1000 IECs or MVL of 1.35 to 1.55 µm
Number of subjects: 0
Study 33038249 — intervention group
Group type: EXPERIMENTAL
Intervention: BIT225 100 mg
Number of subjects: 36
Study 33038249 — intervention group
Group type: EXPERIMENTAL
Intervention: BIT225 200 mg
Number of subjects: 36
Study 33038249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34321182 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Mobilisation (EM)
Number of subjects: 16
Study 32735029 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP (ondansetron + DEX on day 1 + metoclopramide on days 2–3)
Number of subjects: 189
Study 32735029 — intervention group
Group type: EXPERIMENTAL
Intervention: PAL (palonosetron + DEX on day 1)
Number of subjects: 189
Study 32735029 — intervention group
Group type: COMPARATOR
Intervention: DEX (ondansetron on day 1 + DEX on days 1–3)
Number of subjects: 189
Study 35588970 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid phenotypic antibiotic susceptibility testing (AST) with antimicrobial stewardship programme (ASP)
Number of subjects: 116
Study 35588970 — intervention group
Group type: COMPARATOR
Intervention: Conventional AST
Number of subjects: 116
Study 35588970 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid phenotypic AST with ASP
Number of subjects: 116
Study 33745285 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interpersonal psychotherapy (IPT-B)
Number of subjects: 16
Study 33745285 — intervention group
Group type: COMPARATOR
Intervention: Enhanced maternity support services (MSS-Plus)
Number of subjects: 16
Study 32275366 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 70
Study 32275366 — intervention group
Group type: COMPARATOR
Intervention: Medication (Metformin, 500 mg twice a day)
Number of subjects: 70
Study 32275366 — intervention group
Group type: COMPARATOR
Intervention: Medication (Metformin)
Number of subjects: 70
Study 35443967 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) technology
Number of subjects: 117
Study 35443967 — intervention group
Group type: COMPARATOR
Intervention: Control (no VR)
Number of subjects: 117
Study 32721189 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music genre (PMG)
Number of subjects: 20
Study 32721189 — intervention group
Group type: COMPARATOR
Intervention: Non-preferred music genre (NPMG)
Number of subjects: 20
Study 32721189 — intervention group
Group type: COMPARATOR
Intervention: No music (NM)
Number of subjects: 20
Study 35603666 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute cognitive assessment coupled with an electronic medical record-embedded decision tree
Number of subjects: 1200
Study 35603666 — intervention group
Group type: COMPARATOR
Intervention: Current cognitive assessment paradigms in primary care
Number of subjects: 1200
Study 33601996 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 103
Study 33601996 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 103
Study 33601996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 33601996 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PFT
Number of subjects: 103
Study 33601996 — intervention group
Group type: EXPERIMENTAL
Intervention: Lake Louise Questionnaire
Number of subjects: 103
Study 33667960 — intervention group
Group type: EXPERIMENTAL
Intervention: AH with miruco group
Number of subjects: 60
Study 33667960 — intervention group
Group type: COMPARATOR
Intervention: Conventional AH home exercise
Number of subjects: 60
Study 33667960 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-and-see approach)
Number of subjects: 60
Study 32709051 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate (beetroot juice)
Number of subjects: 5
Study 32709051 — intervention group
Group type: COMPARATOR
Intervention: Nitrate‐depleted placebo
Number of subjects: 5
Study 35358207 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) between 3 and 6 months
Number of subjects: 570
Study 32693859 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Food Frequency Questionnaire (SFFQ)
Number of subjects: 99
Study 33361337 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy (pembrolizumab 200 mg IV every 3 weeks + dabrafenib 150 mg orally twice daily + trametinib 2 mg orally once daily)
Number of subjects: 120
Study 33361337 — intervention group
Group type: COMPARATOR
Intervention: Doublet therapy (placebo + dabrafenib 150 mg orally twice daily + trametinib 2 mg orally once daily)
Number of subjects: 120
Study 35337268 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 40
Study 35337268 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve block anaesthesia (PNBA)
Number of subjects: 40
Study 33196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep onset consistency
Number of subjects: 207
Study 33196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 207
Study 33196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality
Number of subjects: 207
Study 33196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Household poverty
Number of subjects: 207
Study 32034789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + Ciprofloxacin
Number of subjects: 45
Study 32034789 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)2
Number of subjects: 45
Study 32034789 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)2 + Ibuprofen
Number of subjects: 45
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions related to symptomology and quality of life
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Various biomedical topics
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbidities
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological management
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiologies
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological management
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational designs
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental designs
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of effect
Number of subjects: 779
Study 33901811 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective measurement tools
Number of subjects: 779
Study 34044675 — intervention group
Group type: COMPARATOR
Intervention: miRNA expression profile in B lymphocytes from wAIHA patients
Number of subjects: 12
Study 34044675 — intervention group
Group type: COMPARATOR
Intervention: stem‐loop qRT‐PCR verification of miRNA sequencing results
Number of subjects: 12
Study 34044675 — intervention group
Group type: COMPARATOR
Intervention: GO functional enrichment and pathway enrichment analyses
Number of subjects: 12
Study 34044675 — intervention group
Group type: COMPARATOR
Intervention: Differentially expressed miRNAs
Number of subjects: 12
Study 32978042 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 5‐min cycle protocol
Number of subjects: 20
Study 32978042 — intervention group
Group type: EXPERIMENTAL
Intervention: 75/5 mmHg protocol
Number of subjects: 20
Study 35086735 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg with acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg with acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: COMPARATOR
Intervention: Placebo with acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg without acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg without acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: COMPARATOR
Intervention: Placebo without acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant acid suppression therapy
Number of subjects: 2639
Study 35086735 — intervention group
Group type: COMPARATOR
Intervention: No acid suppression therapy
Number of subjects: 2639
Study 34918660 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational digital storytelling intervention
Number of subjects: 84
Study 34918660 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 84
Study 36364705 — intervention group
Group type: EXPERIMENTAL
Intervention: Even dietary protein distribution (EVEN, n = 12)
Number of subjects: 24
Study 36364705 — intervention group
Group type: COMPARATOR
Intervention: Skewed dietary protein distribution (SKEWED, n = 12)
Number of subjects: 24
Study 32660919 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed manipulation at the most painful lumbar level
Number of subjects: 148
Study 32660919 — intervention group
Group type: COMPARATOR
Intervention: Generic manipulation of the spine (control group)
Number of subjects: 148
Study 36046011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided right-sided stellate ganglion block with 6 ml 0.25% ropivacaine
Number of subjects: 60
Study 36046011 — intervention group
Group type: COMPARATOR
Intervention: No block (control group)
Number of subjects: 60
Study 33745818 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention research awards
Number of subjects: 14523
Study 33745818 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of existing data
Number of subjects: 14523
Study 33745818 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized interventions
Number of subjects: 14523
Study 33745818 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized interventions addressing leading risk factors in minority health
Number of subjects: 14523
Study 32052503 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN monotherapy (n=136)
Number of subjects: 266
Study 32052503 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN and lamivudine (n=130)
Number of subjects: 266
Study 32052503 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN monotherapy and PEG‐IFN and lamivudine
Number of subjects: 266
Study 32052503 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV RNA level above 5.5 log c/mL at week 12
Number of subjects: 266
Study 35835531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided laparoscopic ovarian cystectomy (UGLOC)
Number of subjects: 94
Study 35835531 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian cystectomy (gold standard treatment)
Number of subjects: 94
Study 33843552 — intervention group
Group type: EXPERIMENTAL
Intervention: Online food composition database developed for 148 commonly consumed foods
Number of subjects: 74
Study 33843552 — intervention group
Group type: COMPARATOR
Intervention: Comparison with existing databases
Number of subjects: 74
Study 35167388 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminist norm condition
Number of subjects: 291
Study 35167388 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional feminine norm condition
Number of subjects: 291
Study 35167388 — intervention group
Group type: COMPARATOR
Intervention: Control norm condition
Number of subjects: 291
Study 33737170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management (CBSM)
Number of subjects: 192
Study 33737170 — intervention group
Group type: COMPARATOR
Intervention: Health promotion (control)
Number of subjects: 192
Study 34547623 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with 200 mg/kg LYC
Number of subjects: 192
Study 34547623 — intervention group
Group type: COMPARATOR
Intervention: Basal diet with 100 �g/kg AFB1
Number of subjects: 192
Study 35136915 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1 g/day)
Number of subjects: 2157
Study 35136915 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation (2000 IU/day)
Number of subjects: 2157
Study 35136915 — intervention group
Group type: COMPARATOR
Intervention: Simple home exercise program (SHEP)
Number of subjects: 2157
Study 34022930 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session videoconference-delivered group pain education class
Number of subjects: 120
Study 34022930 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 120
Study 35594344 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness-based stress reduction (MBSR) program (n = 75)
Number of subjects: 218
Study 35594344 — intervention group
Group type: COMPARATOR
Intervention: Validated, matched active control (n = 73)
Number of subjects: 218
Study 35594344 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL) (n = 70)
Number of subjects: 218
Study 33180688 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Participatory Research (CBPR) RCTs
Number of subjects: 0
Study 35299154 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW group (n = 11) at inclines up to 4%
Number of subjects: 33
Study 35299154 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST group (n = 22) at inclines at or above 6%
Number of subjects: 33
Study 35299154 — intervention group
Group type: COMPARATOR
Intervention: ACSM VO2 prediction
Number of subjects: 33
Study 33677157 — intervention group
Group type: EXPERIMENTAL
Intervention: real rTMS
Number of subjects: 50
Study 33677157 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 50
Study 34508295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg BID
Number of subjects: 0
Study 34508295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID
Number of subjects: 0
Study 34508295 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 0
Study 34508295 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 33845863 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized quality improvement (QI) initiatives
Number of subjects: 24
Study 33845863 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 36270754 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release injectable buprenorphine (BUP-XR)
Number of subjects: 120
Study 36270754 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine (BUP-SL)
Number of subjects: 120
Study 36270754 — intervention group
Group type: COMPARATOR
Intervention: Oral liquid methadone (MET)
Number of subjects: 120
Study 34812466 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of freeze-dried strawberry powder (FDSP)
Number of subjects: 0
Study 34812466 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g FDSP + 25 g of placebo powder
Number of subjects: 0
Study 34812466 — intervention group
Group type: COMPARATOR
Intervention: 50 g placebo powder
Number of subjects: 0
Study 34812466 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g FDSP
Number of subjects: 0
Study 34812466 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g FDSP
Number of subjects: 0
Study 32508323 — intervention group
Group type: COMPARATOR
Intervention: donepezil + placebo (D + P)
Number of subjects: 56
Study 32508323 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil + choline alphoscerate (D + CA)
Number of subjects: 56
Study 35579484 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (20 or 15 mg/d)
Number of subjects: 18
Study 35579484 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 or 2 mg/d)
Number of subjects: 18
Study 35579484 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant or Eszopiclone
Number of subjects: 18
Study 35002810 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group (n = 28)
Number of subjects: 54
Study 35002810 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (n = 26)
Number of subjects: 54
Study 35002810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 54
Study 33260076 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20
Study 33260076 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 35014578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery intervention
Number of subjects: 297
Study 35014578 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline adherence (T1)
Number of subjects: 297
Study 35014578 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 297
Study 35014578 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for non-adherents
Number of subjects: 297
Study 33206268 — intervention group
Group type: EXPERIMENTAL
Intervention: Kata techniques training
Number of subjects: 30
Study 33206268 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training
Number of subjects: 30
Study 33206268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 32538267 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 30
Study 32538267 — intervention group
Group type: COMPARATOR
Intervention: Inert pill
Number of subjects: 30
Study 33662512 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33247023 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychosocial peer-to-peer support intervention
Number of subjects: 0
Study 33247023 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35940831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEN-FAST score-guided management with direct oral penicillin challenge
Number of subjects: 380
Study 35940831 — intervention group
Group type: COMPARATOR
Intervention: Standard care (skin testing followed by oral penicillin challenge if skin testing is negative)
Number of subjects: 380
Study 34535164 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin contact combined with mother’s breastfeeding model
Number of subjects: 148
Study 34535164 — intervention group
Group type: COMPARATOR
Intervention: Routine pacifier sucking training model
Number of subjects: 148
Study 32572223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminococcus and rs150018970 near RAPGEF1 on chromosome 9; P = 1.57 × 10−10
Number of subjects: 2940
Study 32572223 — intervention group
Group type: EXPERIMENTAL
Intervention: Coprococcus and rs561177583 within LINC01787 on chromosome 1; P = 1.57 × 10−10
Number of subjects: 2940
Study 32572223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium and rs4988235 (MCM6/LCT); P < 2.5 × 10−8
Number of subjects: 2940
Study 32572223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis for microbial traits and disease; Caution advised in interpretation due to unclear microbiome-driven effects.
Number of subjects: 2940
Study 35832541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + Avelumab
Number of subjects: 173
Study 35832541 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (single agent)
Number of subjects: 173
Study 33602643 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 170
Study 33602643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 33602643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study 33433595 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAL-enrolled parents
Number of subjects: 269
Study 33433595 — intervention group
Group type: COMPARATOR
Intervention: HEAL-declined parents
Number of subjects: 269
Study 33433595 — intervention group
Group type: COMPARATOR
Intervention: Black parents
Number of subjects: 269
Study 33433595 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents reporting serious infant medical condition
Number of subjects: 269